ArticleOncogene2005
A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.
- Pooled it
- N-glycosylation of ERLIN2 promotes hepatocellular carcinoma progression by enhancing CCNB1 stability.Molecular and cellular biochemistry · 2026Article
- KCNN1 promotes proliferation and metastasis of breast cancer via ERLIN2-mediated stabilization and K63-dependent ubiquitination of Cyclin B1.Carcinogenesis · 2023Article
- BRF2 is mediated by microRNA-409-3p and promotes invasion and metastasis of HCC through the Wnt/β-catenin pathway.Cancer cell international · 2023Article
- BDP1 as a biomarker in serous ovarian cancer.Cancer medicine · 2023Article
- Article
- Article
- Targeting BRF2 in Cancer Using Repurposed Drugs.Cancers · 2021Article
- Silencing of BRF2 inhibits the growth and metastasis of lung cancer cells.Molecular medicine reports · 2020Article
- NSD3S stabilizes MYC through hindering its interaction with FBXW7.Journal of molecular cell biology · 2020Article
- Comprehensive Analysis of Fibroblast Growth Factor Receptor (FGFR) Family Genes in Breast Cancer by Integrating Online Databases and Bioinformatics.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression.Frontiers in immunology · 2020Article
- Article
- Article
- Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.Theranostics · 2018Article
- Cancer- and behavior-related genes are targeted by selection in the Tasmanian devil (Sarcophilus harrisii).PloS one · 2018Article
- Rab coupling protein mediated endosomal recycling of N-cadherin influences cell motility.Oncotarget · 2017Article
- An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.The Journal of molecular diagnostics : JMD · 2017Article
- Evolution of the NET (NocA, Nlz, Elbow, TLP-1) protein family in metazoans: insights from expression data and phylogenetic analysis.Scientific reports · 2016Article
- A pilot study on the prevalence of DNA palindromes in breast cancer genomes.BMC medical genomics · 2016Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amplification of 8p11-12 is a well-known alteration in human breast cancers but the driving oncogene has not been identified. We have developed a high-resolution comparative genomic hybridization array covering 8p11-12 and analysed 33 primary breast tumors, 20 primary ovarian tumors and 27 breast cancer cell lines. Expression analysis of the genes in the region was carried out by using real-time quantitative PCR and/or oligo-microarray profiling. In all, 24% (8/33) of the breast tumors, 5% (1/20) of the ovary tumors and 15% (4/27) of the cell lines showed 8p11-12 amplification. We identified a 1 Mb segment of common amplification that excludes previously proposed candidate genes. Some of the amplified genes did not show overexpression, whereas for others, overexpression was not specifically attributable to amplification. The genes FLJ14299, C8orf2, BRF2 and RAB11FIP, map within the 8p11-12 minimal amplicon, two have a putative function consistent with an oncogenic role, these four genes showed a strong correlation between amplification and overexpression and are therefore the best candidate driver oncogenes at 8p12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.